Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management: Benefits and risks

Michael Spink, Saul Bahn, Robert Glickman

Research output: Contribution to journalArticle

Abstract

Background. Cyclo-oxygenase-2 inhibitors (COX-2 i) demonstrate analgesic efficacy for patients who require gastrointestinal safety. The authors discuss the potential benefits and risks of these novel, but expensive, analgesics when used in dentistry. Methods. The authors conducted a MEDLINE search focused on the subject headings of common analgesic drugs and COX-2 i, using peer-reviewed journals limited to the English language. They selected for review 127 articles that met the criteria. They also tried to identify any randomized controlled trials pertinent to dentistry and indicative of evidence-based medicine. Results. When comparing COX isoforms (COX-1 and COX-2), the authors found that overlapping and mutually exclusively properties coexist. COX-2 i originally were developed to minimize interference with the gastroprotective properties of the COX-1 isoform, while selectively preventing prostanoid synthesis expressed solely at sites of bodily trauma or other inflammation. COX-2 i were found to provide pain relief equal to or slightly exceeding that offered by many mild narcotics. They may avoid some of the serious side effects that can occur with even short-term use of nonselective nonsteroidal anti-inflammatory drugs. Conclusions. The pharmacodynamics of COX-2 i reveal an agent that includes analgesic, anti-inflammatory and gastroprotective properties but also allows for an undesirable disruption of the delicate hemodynamic balance. Clinical Implications. Symptomatic and asymptomatic gastroparietic patients who do not have severe cardiovascular, cerebral or renal ischemic disease benefit from use of COX-2 i. Long-term use of these agents in medically compromised patients may prove disastrous.

Original languageEnglish (US)
Pages (from-to)1439-1448
Number of pages10
JournalJournal of the American Dental Association
Volume136
Issue number10
StatePublished - Oct 2005

Fingerprint

Cyclooxygenase Inhibitors
Acute Pain
Pain Management
Analgesics
Tooth
Dentistry
Protein Isoforms
Evidence-Based Medicine
Narcotics
Non-Steroidal Anti-Inflammatory Agents
MEDLINE
Prostaglandins
Anti-Inflammatory Agents
Language
Randomized Controlled Trials
Hemodynamics
Inflammation
Kidney
Safety
Pain

Keywords

  • Analgesics
  • Cyclo-oxygenase-2 inhibitors
  • Dental pain
  • Pain management

ASJC Scopus subject areas

  • Dentistry(all)

Cite this

Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management : Benefits and risks. / Spink, Michael; Bahn, Saul; Glickman, Robert.

In: Journal of the American Dental Association, Vol. 136, No. 10, 10.2005, p. 1439-1448.

Research output: Contribution to journalArticle

@article{50db3f87831e4357a4b2f0e5de37d0a3,
title = "Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management: Benefits and risks",
abstract = "Background. Cyclo-oxygenase-2 inhibitors (COX-2 i) demonstrate analgesic efficacy for patients who require gastrointestinal safety. The authors discuss the potential benefits and risks of these novel, but expensive, analgesics when used in dentistry. Methods. The authors conducted a MEDLINE search focused on the subject headings of common analgesic drugs and COX-2 i, using peer-reviewed journals limited to the English language. They selected for review 127 articles that met the criteria. They also tried to identify any randomized controlled trials pertinent to dentistry and indicative of evidence-based medicine. Results. When comparing COX isoforms (COX-1 and COX-2), the authors found that overlapping and mutually exclusively properties coexist. COX-2 i originally were developed to minimize interference with the gastroprotective properties of the COX-1 isoform, while selectively preventing prostanoid synthesis expressed solely at sites of bodily trauma or other inflammation. COX-2 i were found to provide pain relief equal to or slightly exceeding that offered by many mild narcotics. They may avoid some of the serious side effects that can occur with even short-term use of nonselective nonsteroidal anti-inflammatory drugs. Conclusions. The pharmacodynamics of COX-2 i reveal an agent that includes analgesic, anti-inflammatory and gastroprotective properties but also allows for an undesirable disruption of the delicate hemodynamic balance. Clinical Implications. Symptomatic and asymptomatic gastroparietic patients who do not have severe cardiovascular, cerebral or renal ischemic disease benefit from use of COX-2 i. Long-term use of these agents in medically compromised patients may prove disastrous.",
keywords = "Analgesics, Cyclo-oxygenase-2 inhibitors, Dental pain, Pain management",
author = "Michael Spink and Saul Bahn and Robert Glickman",
year = "2005",
month = "10",
language = "English (US)",
volume = "136",
pages = "1439--1448",
journal = "Journal of the American Dental Association",
issn = "0002-8177",
publisher = "American Dental Association",
number = "10",

}

TY - JOUR

T1 - Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management

T2 - Benefits and risks

AU - Spink, Michael

AU - Bahn, Saul

AU - Glickman, Robert

PY - 2005/10

Y1 - 2005/10

N2 - Background. Cyclo-oxygenase-2 inhibitors (COX-2 i) demonstrate analgesic efficacy for patients who require gastrointestinal safety. The authors discuss the potential benefits and risks of these novel, but expensive, analgesics when used in dentistry. Methods. The authors conducted a MEDLINE search focused on the subject headings of common analgesic drugs and COX-2 i, using peer-reviewed journals limited to the English language. They selected for review 127 articles that met the criteria. They also tried to identify any randomized controlled trials pertinent to dentistry and indicative of evidence-based medicine. Results. When comparing COX isoforms (COX-1 and COX-2), the authors found that overlapping and mutually exclusively properties coexist. COX-2 i originally were developed to minimize interference with the gastroprotective properties of the COX-1 isoform, while selectively preventing prostanoid synthesis expressed solely at sites of bodily trauma or other inflammation. COX-2 i were found to provide pain relief equal to or slightly exceeding that offered by many mild narcotics. They may avoid some of the serious side effects that can occur with even short-term use of nonselective nonsteroidal anti-inflammatory drugs. Conclusions. The pharmacodynamics of COX-2 i reveal an agent that includes analgesic, anti-inflammatory and gastroprotective properties but also allows for an undesirable disruption of the delicate hemodynamic balance. Clinical Implications. Symptomatic and asymptomatic gastroparietic patients who do not have severe cardiovascular, cerebral or renal ischemic disease benefit from use of COX-2 i. Long-term use of these agents in medically compromised patients may prove disastrous.

AB - Background. Cyclo-oxygenase-2 inhibitors (COX-2 i) demonstrate analgesic efficacy for patients who require gastrointestinal safety. The authors discuss the potential benefits and risks of these novel, but expensive, analgesics when used in dentistry. Methods. The authors conducted a MEDLINE search focused on the subject headings of common analgesic drugs and COX-2 i, using peer-reviewed journals limited to the English language. They selected for review 127 articles that met the criteria. They also tried to identify any randomized controlled trials pertinent to dentistry and indicative of evidence-based medicine. Results. When comparing COX isoforms (COX-1 and COX-2), the authors found that overlapping and mutually exclusively properties coexist. COX-2 i originally were developed to minimize interference with the gastroprotective properties of the COX-1 isoform, while selectively preventing prostanoid synthesis expressed solely at sites of bodily trauma or other inflammation. COX-2 i were found to provide pain relief equal to or slightly exceeding that offered by many mild narcotics. They may avoid some of the serious side effects that can occur with even short-term use of nonselective nonsteroidal anti-inflammatory drugs. Conclusions. The pharmacodynamics of COX-2 i reveal an agent that includes analgesic, anti-inflammatory and gastroprotective properties but also allows for an undesirable disruption of the delicate hemodynamic balance. Clinical Implications. Symptomatic and asymptomatic gastroparietic patients who do not have severe cardiovascular, cerebral or renal ischemic disease benefit from use of COX-2 i. Long-term use of these agents in medically compromised patients may prove disastrous.

KW - Analgesics

KW - Cyclo-oxygenase-2 inhibitors

KW - Dental pain

KW - Pain management

UR - http://www.scopus.com/inward/record.url?scp=27144488172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144488172&partnerID=8YFLogxK

M3 - Article

VL - 136

SP - 1439

EP - 1448

JO - Journal of the American Dental Association

JF - Journal of the American Dental Association

SN - 0002-8177

IS - 10

ER -